Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MNPR 101 Ac-225

Next Previous
X
Search
Drug Profile

MNPR 101 Ac-225

Alternative Names: MNPR 101- AC; MNPR-101 radioimmunotherapeutic; MNPR-101 RIT; MNPR-101-Ac225; MNPR-101-PCTA; PCTA-Ac225- MNPR-101; PCTA-MNPR-101

Latest Information Update: 16 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Monopar Therapeutics; NorthStar Medical Technologies
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Discontinued COVID 2019 infections; Immunological disorders

Most Recent Events

  • 09 May 2024 Monopar Therapeutics in collaboration with Cancer Science Institute of Singapore plans first-in-human (FIH) phase I trial for Cancer (Late stage disease) as early as the end of 2024 or first quarter of 2025
  • 22 Feb 2024 Pharmacodynamics data from a preclinical trial in Triple negative breast cancer and Pancreatic cancer released by Monopar Therapeutics
  • 12 Jul 2023 Monopar Therapeutics and Cancer Science Institute of Singapore agree to co-develop MNPR 101 Ac in USA for Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top